Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16612931 | 1.00 | HRH3 (0.46) | HRH3KCNH2ADRA1ACHIACYP3A4 | |
| SCHEMBL12181943 | 0.89 | HRH3 (0.46) | HRH3KCNH2CYP3A4GPR119 | |
| SCHEMBL12181944 | 0.88 | GPR119 (0.40) | HRH3KCNH2GPR119 | |
| SCHEMBL12181957 | 0.84 | GPR119 (0.43) | HRH3ADRA1ACHIAGPR119 | |
| SCHEMBL16612501 | 0.84 | HRH3 (0.47) | HRH3KCNH2CYP3A4 | |
| SCHEMBL2596398 | 0.84 | HRH3 (0.47) | HRH3KCNH2CYP3A4 | |
| SCHEMBL12181996 | 0.83 | GPR119 (0.43) | HRH3KCNH2CYP3A4GPR119 | |
| SCHEMBL12182151 | 0.82 | GRIN2D (0.51) | HRH3KCNH2CHIACYP3A4 | |
| SCHEMBL2596385 | 0.82 | HRH3 (0.43) | HRH3KCNH2CYP3A4 | |
| SCHEMBL12182110 | 0.82 | HRH3 (0.44) | HRH3KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569305-B1 | SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-04-08 | — | — | EP | claimed |
| US-8623877-B2 | Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-01-07 | — | — | US | claimed |
| US-20130059838-A1 | SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | claimed |
| EP-2569305-B1 | SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-04-08 | — | — | EP | disclosed |
| EP-2569305-B1 | SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-04-08 | — | — | EP | disclosed |
| US-8623877-B2 | Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-01-07 | — | — | US | disclosed |
| US-8623877-B2 | Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-01-07 | — | — | US | disclosed |
| US-20130059838-A1 | SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| US-20130059838-A1 | SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059838-A1 | SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HNMT, HRH4 | HRH3 1/4885KCNH2 1274/4885ADRA1A 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.